Partial
Partially Aligned
Patient Risk:
Low
Summary
Most claims about sildenafil/Viagra and generic availability are outside the provided FDA label excerpts and therefore are unsupported for this audit. The claim about FDA-approved indication (ED) matches the provided label excerpt. No contraindications/boxed warnings/detailed dosing were claimed by the AI response.
Category Scores
Accurate Statements
Viagra is a prescription medication that treats erectile dysfunction (ED) in men.
FDA label excerpt Section 1: “VIAGRA is indicated for the treatment of erectile dysfunction.”
Unsupported Statements
Viagra is also known as sildenafil.
The provided label excerpts do not explicitly state that Viagra is synonymous with sildenafil; they mention sildenafil as the active ingredient/mechanism (e.g., Section 12), but the audit was limited to explicit support for this exact claim in the supplied excerpts.
Generic sildenafil is available at a lower cost than brand-name Viagra.
No information in the provided label excerpts addresses pricing or cost comparisons between brand and generic products.
Generic versions might not be identical in terms of quality or dosage compared with brand-name Viagra.
No information in the provided label excerpts addresses generic equivalence, quality, or dosage comparability.
Pfizer's patent for Viagra (sildenafil) expired in several countries, including the United States, in 2017.
No information in the provided label excerpts addresses patent status or expiration dates.
Pfizer's patent expiration allows generic versions to be manufactured by other companies, which can help drive down prices.
No information in the provided label excerpts addresses patent effects, manufacturing authorization, or drivers of price changes.
Contradictions
Important Omissions
No dosing, contraindications, boxed warnings, or safety/interaction details were provided in the AI claims; however, the user did not request these specifics. Only ED indication was claim-supported by the provided excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Unsupported claims are largely non-prescribing (pricing/patent history/equivalence) and do not directly add dosing or contraindication errors based on the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Several statements are not supported by the provided FDA label excerpts (e.g., generic pricing/equivalence and patent expiration details).
Suggested Improvement
Limit statements to what is supported by the provided label excerpts (e.g., indication for erectile dysfunction and the product/sildenafil relationship as explicitly stated), or provide the specific label sections that support the omitted topics.